Scholar Rock Holding Corp (SRRK) - News Archive

2024 has proven to be a landmark year for Scholar Rock, a biopharmaceutical company focused on developing innovative treatments for serious diseases like spinal muscular atrophy (SMA) and cardiometabolic disorders. Scho...

: Scholar Rock, a biopharmaceutical company focused on pioneering therapies for spinal muscular atrophy (SMA) and other serious conditions, is set to present additional clinical data from its Phase 3 SAPPHIRE trial at t...

: Scholar Rock Holding Corp announces new preclinical data for its investigational therapeutic candidate SRK-439, demonstrating a significant increase in lean mass and a greater reduction in fat mass when used in conjun...

On November 12, 2024, Scholar Rock Holding Corp is set to host a conference call to discuss its financial results for the third quarter of 2024, alongside an important business update. The call comes against a backdrop...

Scholar Rock, a biopharmaceutical company listed on NASDAQ as SRRK, has reported significant progress in its development of apitegromab, a pioneering therapy for spinal muscular atrophy (SMA). The company announced that...

Scholar Rock Announces New Employee Inducement Grants and Encouraging Data from SRK-181 Phase 1 DRAGON Trial CAMBRIDGE, Mass. Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company known for its late-stage advancement...

Scholar Rock Announces New Employee Inducement Grants Amidst Financial Struggles Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) In a recent disclosure, Scholar Rock (NASDAQ: SRR...

Scholar Rock Announces New Employee Inducement Grants: A Strategic Move for Future GrowthScholar Rock (NASDAQ: SRRK), a trailblazer in the biopharmaceutical industry, recently unveiled significant developments that disp...

In a recent press release, Scholar Rock, a late-stage biopharmaceutical company, announced promising data from its Phase 1 DRAGON trial of SRK-181. This selective inhibitor of latent TGF1 activation, when used in combin...

Scholar Rock s SRK-181 Shows Promise in Advanced Solid Tumor Treatment: Phase 1 DRAGON Trial Results Unveiled CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a pioneering biopharmaceutical company dedicated to developin...

Scholar Rock, a late-stage biopharmaceutical company specializing in research and development of innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other protein growth factor-relate...

Throughout 2023, Scholar Rock made notable progress in advancing its antimyostatin pipeline, particularly with apitegromab. The Phase 3 clinical-stage biopharmaceutical company successfully completed the enrollment of i...

In a recent announcement, Scholar Rock, a leading late-stage biopharmaceutical company, shared their financial results and corporate updates for the full year 2023. The company is dedicated to developing innovative trea...

Scholar Rock’s Recent Inducement Grants Questioned Amidst Financial StrugglesBy In a recent announcement, late-stage biopharmaceutical company Scholar Rock (NASDAQ: SRRK) revealed that it granted inducement equity award...

Scholar Rock Grants Inducement Equity Awards to New Employees amidst Company GrowthScholar Rock (NASDAQ: SRRK) has recently announced the granting of inducement equity awards to four newly hired employees, totaling 131,...

In a recent announcement, Scholar Rock, a pioneering biopharmaceutical company focused on innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases, revealed the addi...

Scholar Rock, a late-stage biopharmaceutical company, has released data from recent preclinical trials, presenting the potential of its promising innovations SRK-439 and SRK-181 in the treatment of cardiometabolic disor...

Scholar Rock, a prominent biopharmaceutical company specializing in innovative treatments for various diseases, has recently achieved a significant milestone the FDA clearance of its Investigational New Drug (IND) appli...

Scholar Rock, a clinical-stage biopharmaceutical company dedicated to developing treatments for serious diseases involving protein growth factors, recently announced the granting of inducement equity awards to newly hir...

Scholar Rock: Advancing Cutting-Edge Therapies for Spinal Muscular Atrophy and MoreCambridge-based biopharmaceutical company Scholar Rock (NASDAQ: SRRK) has revealed its recent corporate updates and outlined its key pri...